Edesa Biotech (EDSA) risk factors
Item 1A of every Edesa Biotech, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors55 risks4 new2 dropped6 reworded
Edesa Biotech added risks regarding NIH grant funding caps, global trade tariffs, unproven drug mechanisms, and orphan drug designations. Insider ownership percentages shifted slightly. Preferred share details were updated to include Series B-1 classes.
Filed Dec 12, 2025 - FY2024 10-K risk factors53 risks
Edesa Biotech faces significant operating losses with an accumulated deficit of $58.6 million and needs substantial additional capital to fund clinical trials. The company depends heavily on third parties for manufacturing monoclonal antibodies and conducting clinical trials for candidates like EB05, EB06, EB01, and EB07. Operations are concentrated around specific disease targets including vitiligo, chronic ACD, ARDS, and pulmonary fibrosis.
Filed Dec 13, 2024